Tapentadol
- Generic Name
- Tapentadol
- Brand Names
- Nucynta
- Drug Type
- Small Molecule
- Chemical Formula
- C14H23NO
- CAS Number
- 175591-23-8
- Unique Ingredient Identifier
- H8A007M585
- Background
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.
...
- Indication
用于治疗严重到需要阿片类镇痛剂且替代治疗不充分的急性疼痛。
- Associated Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Severe Acute Pain, Severe Pain
- Associated Therapies
- -
A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 91
- Registration Number
- NCT01124617
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
- Target Recruit Count
- 667
- Registration Number
- NCT00986180
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 224
- Registration Number
- NCT00983073
- Locations
- 🇬🇧
Site 1, Solihull, United Kingdom
🇪🇸Site 2, A Coruna, Spain
🇬🇧Site 4, Swansea, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath